This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Vodafone (VOD.L) - Reported a £6.1bn loss for the year to end-March, dragged lower by its Indian unit it is merging with Idea Cellular. The groups forecast growth in earnings and free cash flow for the current year of 4-8% and free cash flow of about €5bn, up from €4.1bn in the previous year. Closing price 211.10p (Reuters)
DCC (DCC.L) – FY pretax profit rose 23.7% to £268.2m, Final dividend up 16.3% to 74.63p p/sh, FY revenue - continuing (excluding. Dcc energy) £3.196bln vs. £2.932bln year ago. FY operating profit - continuing £345m vs. £285.3m year ago, "Expect that coming year will be another year of profit growth and development. Closing Price 7365p (Reuters)
EasyJet (EZJ.L) – Saw H1 revenue miss expectations marginally by 2.7% coming in at £1.83bn against expectations of £1.88bn reporting a bigger than expected pretax loss of £236m against £176m expected and revenue per seat falling 4.9%. Closing price 1310.00p (Bloomberg)
Crest Nicholson Holdings Plc (CRST.L) – Trading continues to be in line with expectations, remaining on track to deliver growth in unit sales and saw 10% in revenues for full year to 31 October 2017, unit completions for H1 of 2017 financial year fell y-o-y, however forward sales for 2017 year including year to date completions are 5% up y-o-y. Closing price 636.50p (Reuters)
Premier Foods (PFD.L) - Reported lower sales and earnings citing tough trading conditions, full-year group underlying sales fell 1.4% to £790.4m. Adjusted profit before tax fell 11.8% to £74.2m, adjusted earnings per share fell 12.2%, now giving focus to revenue growth, cost efficiencies and cash generation. Closing price 43.00p (Reuters)
AstraZeneca Plc (AZN.L) - filed a lawsuit in a London court against former executive Luke Miels saying he’s in violation of his employment agreement, four months after rival drugmaker GlaxoSmithKline Plc announced it was poaching him to run its largest business. Closing price 5194p (Bloomberg)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research